Gynecologic Oncology | Specialty

Targeted Therapy Options for Advanced Ovarian Cancer

July 30th 2019

Systemic Therapy Selection for Advanced EOC

July 30th 2019

Dr. Van Tine on Collaboration and Clinical Trials in Uterine Sarcoma

July 21st 2019

Brian A. Van Tine, MD, PhD, discusses collaboration within the sarcoma field and the importance of clinical trials for advancing treatment.

Evaluating Surgery and Angiogenesis Inhibition in Recurrent Ovarian Cancer

July 21st 2019

Angeles Alvarez Secord, MD, discusses the available treatment modalities for patients with platinum-sensitive and -resistant recurrent ovarian cancer.

Ongoing Research With Novel Approaches Continues in Uterine Sarcomas

July 18th 2019

Brian Van Tine, MD, highlights the latest developments in soft tissue sarcoma, including data from key trials and further research being conducted in the rare tumor field.

Quest Continues to Extend Reach of Immunotherapy, PARP Inhibitors in Ovarian Cancer

July 17th 2019

Matthew Powell, MD, discusses the trials that are generating excitement for combination immunotherapy as well as the impact of PARP inhibitors in the treatment of patients with ovarian cancer.

SOLO-1 Data Encourage Molecular Testing Immediately at Ovarian Cancer Diagnosis

July 17th 2019

Thomas Herzog, MD, discusses recent changes in the ovarian cancer landscape, specifically PARP inhibitors and the optimal use of bevacizumab.

Frontline Maintenance Niraparib Improves PFS in Ovarian Cancer

July 15th 2019

Niraparib as a maintenance treatment demonstrated a statistically significant improvement in progression-free survival compared with placebo in patients with ovarian cancer following first-line platinum-based chemotherapy, regardless of biomarker status, meeting the primary endpoint of the phase III PRIMA (ENGOT-OV26/GOG-3012) trial.

Dr. Cristea on Investigational Maintenance Strategies in Ovarian Cancer

July 2nd 2019

Mihaela C. Cristea, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses investigational maintenance strategies in advanced ovarian cancer.

Dr. Hong on the Mechanism of Action of Tisotumab vedotin in Cervical Cancer

June 25th 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

FDA Grants Priority Review to Niraparib for Late-Stage Ovarian Cancer

June 25th 2019

The FDA has granted a priority review designation to a supplemental biologics license application for niraparib for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with ≥3 or more prior chemotherapy regimens, and who have either a BRCA mutation or have homologous recombination deficiency and progressed >6 months after their last platinum-based chemotherapy.

Dr. Mirza on the Rationale for the AVANOVA Trial in Recurrent Ovarian Cancer

June 21st 2019

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the rationale for the AVANOVA study in patients with platinum-sensitive recurrent ovarian cancer.

Olaparib Approved in Japan for Frontline Maintenance in Ovarian Cancer

June 19th 2019

Japan’s Pharmaceuticals and Medical Devices Agency approved olaparib as a maintenance treatment for patients with BRCA-mutant ovarian cancer after undergoing first-line chemotherapy.

Moving Molecular Testing to the Frontlines of Ovarian Cancer

June 10th 2019

Mihaela C. Cristea, MD, emphasizes the use of molecular testing over tumor testing in ovarian cancer.

Sorting Through Unanswered Questions in Ovarian Cancer

June 10th 2019

Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.

SOLO-1 Olaparib Trial Fosters Novel Applications of Frontline Maintenance in Ovarian Cancer

June 7th 2019

Mihaela C. Cristea, MD, discusses the impact of the SOLO-1 trial on current approaches to frontline maintenance therapy as well as the trials that are underway with niraparib, rucaparib, and the investigational PARP inhibitor veliparib.

Dr. Oaknin on the Safety Profile of Dostarlimab in Endometrial Cancer

May 29th 2019

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the safety profile of dostarlimab (TSR-042) in patients with endometrial cancer.

Managing Obesity in Survivors of Gynecologic Cancer

May 25th 2019

With nearly 40% of the adult population in the Unites States classified as obese, gynecologic oncologists must be ready to address the specific needs and considerations for this population, including for patients who have entered survivorship.

FDA Grants LN-145 Breakthrough Designation for Cervical Cancer

May 24th 2019

The FDA has granted a breakthrough therapy designation to the tumor-infiltrating lymphocyte therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy.

Dr. Backes on the Utility of Sentinel Lymph Node Mapping in Cervical Cancer

May 24th 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, at The Ohio State University Comprehensive Cancer Center, discusses the utility of sentinel lymph node mapping in patients with cervical cancer.